Stockreport

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences, Inc  (NERV) 
Last minerva neurosciences, inc earnings: 3/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.minervaneurosciences.com/investor-relations
PDF Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population [Read more]